key: cord-0980772-zwgk21f8 authors: Hoffman, T.; Kolstad, L.; Ronnberg, B.; Lundkvist, A. title: Evaluation of production lots of a rapid point-of-care lateral flow serological test intended for identification of IgM and IgG against the N-terminal part of the spike protein (S1) of SARS-CoV-2 date: 2020-09-01 journal: nan DOI: 10.1101/2020.08.27.20182923 sha: 4d4512b0db63d0c2f24660d948c37131fc8c90ed doc_id: 980772 cord_uid: zwgk21f8 Background and objectives: Several antibody tests are available to detect SARS-CoV-2 specific antibodies, many of which address different antigens. Rapid point-of-care (POC) tests have been doubted due to an eventual risk of production errors, although it is unstudied whether such error would affect test sensitivity and/or specificity. We aimed to evaluate two separate production lots of a commercially available test intended for rapid detection of IgM and IgG against the N-terminal part of the SARS-CoV-2 spike protein (S1). Materials and methods: Serum samples from individuals with confirmed SARS-CoV-2 infection, by RT-PCR and/or serology, and pre-COVID-19 negative control sera gathered from a biobank during 2018 were collected. The presence of anti-S1 IgM/IgG was verified by an in-house Luminex-based serological assay, serving as reference method. The index test was a commercially available rapid POC-test (the COVID-19 IgG/IgM Rapid Test Cassette [Zhejiang Orient Gene Biotech Co Ltd, Huzhou, Zhejiang, China/Healgen Scientific, LLC, U.S.A.]). Results: One hundred samples were verified positive for anti-S1 IgG (median fluorescence intensity (MFI) greater than or equal to 900) and 74 for anti-S1 IgM (MFI greater than or equal to 700), confirmed by RT-PCR (n=90) and/or serology (n=89). None of the negative controls (n=200; MFI <300) had SARS-CoV-2 anti-S1 IgM, while one tested positive for SARS-CoV-2 anti-S1 IgG. For the two lots, the sensitivities of the rapid test were 93.2% (69/74; 95% CI: 85.1% - 97.1%) and 87.8% (65/74; 95% CI: 78.5% - 93.5%) for IgM, respectively 93.0% (93/100; 95% CI: 86.3% - 96.6%) and 100.0% for IgG (100/100; 95% CI: 96.3% - 100.0%). The specificity for both lots was 100% for IgM (200/200; 95% CI: 98.1% - 100%) and 99.5% for IgG (199/200; 95% CI: 97.2% - 99.9%). The positive predictive value was 100% for IgM and 98.9% and 99.0% for IgG. The negative predictive value was 95.7% and 97.6% for IgM, and 96.6% and 100.0% for IgG. Conclusion: The rapid POC-test used in this study is suitable to assess SARS-CoV-2 anti-S1 specific IgM/IgG, as a measure of previous virus exposure on an individual level. While the specificity was not affected by production lot, external validation of separate lots of rapid POC-tests is encouraged to ensure high sensitivity before market introduction. and IgG against the N-terminal part of the SARS-CoV-2 spike protein (S1). Results: One hundred samples were verified positive for anti-S1 IgG (median fluorescence 31 intensity (MFI) ≥900) and 74 for anti-S1 IgM (MFI ≥700), confirmed by RT-PCR (n=90) 32 and/or serology (n=89). None of the negative controls (n=200; MFI <300) had SARS-CoV-2 33 anti-S1 IgM, while one tested positive for SARS-CoV-2 anti-S1 IgG. For the two lots, the 34 sensitivities of the rapid test were 93.2% (69/74; 95% CI: 85.1% -97.1%) and 87.8% (65/74; 35 95% CI: 78.5% -93.5%) for IgM, respectively 93.0% (93/100; 95% CI: 86.3% -96.6%) and 36 100.0% for IgG (100/100; 95% CI: 96.3% -100.0%). The specificity for both lots was 100% 37 for IgM (200/200; 95% CI: 98.1% -100%) and 99.5% for IgG (199/200; 99.9%). The positive predictive value was 100% for IgM and 98.9% and 99.0% for IgG. The 39 negative predictive value was 95.7% and 97.6% for IgM, and 96.6% and 100.0% for IgG. The rapid POC-test used in this study is suitable to assess SARS-CoV-2 anti-S1 41 specific IgM/IgG, as a measure of previous virus exposure on an individual level. While the 42 specificity was not affected by production lot, external validation of separate lots of rapid 43 POC-tests is encouraged to ensure high sensitivity before market introduction. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. share structural similarities and are composed of 16 non-structural proteins and four structural 55 proteins: the spike (S), envelope, membrane, and nucleocapsid (N) proteins. In turn, the N-56 terminal part of the S protein (S1) contains a receptor-binding domain (RBD) that specifically 57 recognizes the angiotensin-converting enzyme 2 (ACE2) receptor in humans, which SARS- CoV-2 has been identified to bind to in order to infect the human host. 4-6 There is convincing evidence that a majority of patients with past COVID-19 60 develop neutralizing antibodies against the virus. 7 For detection of antibodies, there are 61 several available serological assays developed to identify individuals with recent and past 62 exposure and to assess the extent of exposure in a population. In turn, this might help to 63 decide on application, enforcement or relaxation of containment measures. As proper 64 neutralization tests are cumbersome, time-consuming and require biosafety level 3 65 laboratories, there are several available tests that address different SARS-CoV-2 specific 66 antigens, the most common being the N-protein or the S-protein. In a recent population-based study from Spain, different seroprevalences were 68 estimated by a chemiluminescent microparticle immunoassay (CMIA) for detection of anti-N 69 IgG, and a lateral flow immunochromatographic assay (LFIA) for detection of anti-S1 IgG. 3 Whether the difference in estimated seroprevalence could be explained by dynamic 71 appearance of antibodies targeting the different viral proteins or whether the rapid point-of-72 care (POC) test did not have as good performance as the CMIA-test, is unknown. Available serological methods to date either rely on quantitative laboratory-74 based assays or on qualitative LFIAs. While the lateral flow tests have the advantage of being 75 a POC-analysis where results can be given directly to the patient within minutes from sample 76 collection, rapid POC-tests have been attributed a potential risk of production errors that may 77 result in unreliable performance of the test. There is, however, to our knowledge no study 78 published to date investigating whether the sensitivity and/or specificity varies between 79 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182923 doi: medRxiv preprint 4 production lots of a rapid test. In this study, we therefore aimed to evaluate two separate 80 production lots of one commercially available rapid POC-test (the COVID-19 IgG/IgM Rapid 81 Test Cassette [Zhejiang Orient Gene Biotech Co Ltd, Huzhou, Zhejiang, China] ) and its 82 accuracy in identifying anti-S1 IgM/IgG. As reference standard, presence of SARS-CoV-2 83 S1-specific IgM and IgG in positive controls were verified with an in-house Luminex-based 84 COVID-19 assay (Magpix technology, Luminex Corporation). The study was approved by the Swedish Ethical Review Authority (2020-02047). Reference method 102 Samples were pre-specified when evaluating the index test. The reference method used was a 103 Luminex-based (Magpix technology, Luminex Corporation) SARS-CoV-2-specific assay, 104 developed in-house and used due to high specificity and sensitivity in detecting SARS-CoV-2 105 S1-specific IgM and IgG (manuscript in preparation). Samples with confirmed SARS-CoV-2 106 infection that tested positive for SARS-CoV-2 S1-specific IgG with a median fluorescence 107 intensity (MFI) ≥900 were used as reference for positive IgG-samples. Of those, samples 108 positive for SARS-CoV-2 S1-specific IgM with an MFI ≥700 served as reference for positive 109 IgM-samples. Samples with an MFI <300 were considered negative for anti-S1 IgM and IgG. All samples were from unique individuals and analysed anonymously. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. Zhejiang, China / Healgen Scientific LLC, Houston, USA). This test targets anti-S1 IgM and 118 IgG. Briefly, 5 µl of serum were added to the test slide, followed by 80 µl of the buffer 119 provided in the kit. The results were read after 10 minutes (max 15 min) by the naked eye. Test results were blinded to the assessors of the index test, as well as to the assessors of the 121 reference standard. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. In this study, we evaluated different production lots of a commercially available rapid POC-172 test for detection of IgM and IgG against the S1-protein of SARS-CoV-2. The test displayed a 173 high sensitivity and specificity when compared against a Luminex-based (Magpix 174 technology) SARS-CoV-2-specific assay. Comparing two different production lots, the 175 sensitivity was 87.8% and 93.2% for IgM and 93.0% and 100.0% for IgG. Regarding the 176 specificity, it remained at 100.0% and 99.5% for IgM and IgG, respectively. A high 177 performance of the rapid test has also been reported elsewhere, with a specificity ranging 178 from 97.5% to 100% for IgG and 100% for IgM, and a sensitivity ranging from 96.7% to 98% 179 for IgG and 68% to 100% for IgM. 10 The Swedish Public Health Agency has warranted a IgG 180 specificity of ≥99.5% and a sensitivity of ≥90% for COVID-19 related serological assays to 181 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182923 doi: medRxiv preprint 7 be recommended as an assay for assessment of antibody presence on an individual level. 11 In 182 this study, both investigated production lots of the investigated POC-test reached that 183 standard and may, thus, be suitable for antibody screening in Sweden. Differences in sensitivity of the two production lots in the current study might 185 be explained by small differences in the amount of antigen added during production of the 186 rapid test, which could lead to a weaker qualitative response and, thus, effecting the 187 sensitivity of the test. Different amounts, and not varying quality, of the antigen would also 188 explain why the test was still highly specific in both lots. Previously, we have reported a In a recent population-based study from Spain; more than 51,000 individuals 195 were tested by a CMIA for detection of anti-N IgG and the same rapid POC-test as 196 investigated in the current study, which targets anti-S1 IgM/IgG. 3 Comparing the two tests, to the inter-individual differences in dynamics of these antibody subtypes, it has been 213 suggested that a combination of antibody tests, targeting different viral proteins, may be the 214 best strategy in order to increase sensitivity and/or specificity when screening for SARS-CoV-215 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182923 doi: medRxiv preprint 8 2 specific antibodies. 3 However, as anti-S antibodies can block the ACE2-receptor and thus 216 prevent SARS-CoV-2 from infecting the human host, 13 a positive result from the studied rapid 217 POC-test could indicate immunity against re-infection as long as adequate titers are upheld. To the best of our knowledge, this is the first study to evaluate the impact of 219 production lots on the performance of a rapid POC-test intended for detection of SARS-CoV-220 2 specific anti-S1 IgM and IgG. The world is looking for serological assays that can help to 221 decide on relaxation of containment measures and POC-tests are optimal for such purpose 222 given the lower associated costs, easier implementation, and the potentially increased uptake 223 as compared with laboratory-based assays. The fact that the PPV and NPV for IgG remained 224 high over a broad range of prevalence indicates that the investigated rapid POC-test is suitable 225 for screening of SARS-CoV-2 specific IgG antibodies in regions with varying prevalence and 226 during different stages of the pandemic, and therefore could aid in determining containment 227 measures. The observed differences in sensitivity between the two production lots highlight 228 the need for external validation of each production lot before a rapid POC-test is made 229 available on the market. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020 . . https://doi.org/10.1101 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182923 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 1, 2020. . https://doi.org/10. 1101 A Novel Coronavirus from Patients with Pneumonia in China Prevalence of SARS-CoV-2 in Spain COVID): a nationwide, population-based seroepidemiological study Antigenicity of the SARS-CoV-2 Spike Glycoprotein Receptor Recognition by the Novel 258 Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of 259 SARS Coronavirus Structural basis of receptor recognition by SARS-CoV-2 Evaluating the association of clinical characteristics perpetuity.preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint inThe copyright holder for this this version posted September 1, 2020. . https://doi.org/10. 1101